Combined Oral Contraceptives: A General Overview

Topics: Antipsychotics | Women's Issues in Psychiatry

Given the teratogenicity of certain psychiatric drugs like mood stabilizers and antipsychotics, it is logical and responsible to offer contraception to patients for whom these drugs are prescribed. However, actually doing so can be complicated. Ideally, a patient has a psychiatrist managing her mental health care and a primary care physician or gynec

Side Effects of Antipsychotics in Children

Topics: Antipsychotics | Child Psychiatry

Can Omega 3s Prevent Psychotic Disorders?

Topics: Antipsychotics | Natural Medications

Saphris and Fanapt: Two New Antipsychotics

Topics: Antipsychotics

You've probably heard about Fanapt (iloperidone) and Saphris (asenapine), two antipsychotics that have recently won FDA approval for the acute treatment of schizophrenia, and, in the case of Saphris, for the treatment of manic and mixed episodes of bipolar disorder. Are these more “me too” atypicals or do they represent novel treatment options? Let�

Topics in the Treatment of Schizophrenia

Topics: Antipsychotics

Abilify for Depression and Bipolar Disorder: A Meta-Analysis

Topics: Antipsychotics

Antipsychotics: Small Benefits for Depression

Topics: Antipsychotics

Discontinuing Antipsychotics May Decrease Mortality Risk in Dementia

Topics: Antipsychotics

Small Efficacy Differences Between Atypicals in Treating Schizophrenia

Topics: Antipsychotics

Prescribing Atypical Antipsychotics: What are the Risks?

Topics: Antipsychotics

Over the past several years, the use of antipsychotics has expanded dramatically. Aside from the traditional indication, schizophrenia, various members of this class have received FDA approval for bipolar mania, bipolar depression, major depression, and autism, and increasingly they are used off-label for anxiety, insomnia, and agitation. As with any

Atypicals Roughly Equivalent to Molindone for Youth Psychosis

Topics: Antipsychotics

Vanda’s antipsychotic candidate iloperidone rejected by FDA

Topics: Antipsychotics

Introducing...Fanapta!

Topics: Antipsychotics

You’ve probably heard about Fanapta (iloperidone), a new antipsychotic marketed by Vanda Pharmaceuticals. No, it hasn’t been approved officially yet, but it is likely to win approval in July, and the company has already been taking out teaser ads in the journals and has even sponsored a touring promotional CME program run by Stephen Stahl. Is it

Antipsychotic Updates

Topics: Antipsychotics

Here is some selective coverage of interesting recent developments in antipsychotic medications. Invega TCPR gave Invega (paliperidone ER) a lukewarm review soon after it was first released (see March 2007: “Invega: Can you say ‘patent extender?’”). At that time we were able to pinpoint only two potentially meaningful advantages of Invega

The First Antipsychotic

Topics: Antipsychotics

The first antipsychotic medication was discovered by a French naval surgeon named Henri Laborit. Dr. Laborit had little interest in psychiatry, but was avidly seeking a way to better treat wounded soldiers who were in shock. In June of 1951, he obtained a medication from the French Pharmaceutical firm Rhone-Poulenc that was billed as effective in “pot

Antipsychotics and Meta-analyses: A Basic Survey

Topics: Antipsychotics

Tamoxifen appears effective for mania

Topics: Antipsychotics

Side Effects of Antipsychotics in the Elderly

Topics: Antipsychotics

Placebo more effective than antipsychotics for aggression in mental retardation

Topics: Antipsychotics

Discontinuing mood stabilizers often leads to relapse during pregnancy

Topics: Antipsychotics | Women's Issues in Psychiatry